VELMETIA 50/500 sitagliptin (as phosphate monohydrate) 50 mg and metformin hydrochloride 500 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

velmetia 50/500 sitagliptin (as phosphate monohydrate) 50 mg and metformin hydrochloride 500 mg tablet blister pack

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 64.25 mg (equivalent: sitagliptin, qty 50 mg); metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; microcrystalline cellulose; sodium stearylfumarate; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - velmetia (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see sections 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Janumet New Zealand - English - Medsafe (Medicines Safety Authority)

janumet

merck sharp & dohme (new zealand) limited - metformin hydrochloride 500mg; sitagliptin phosphate monohydrate 64.25mg equivalent to sitagliptin 50 mg;  ;   - film coated tablet - 50mg/500mg - active: metformin hydrochloride 500mg sitagliptin phosphate monohydrate 64.25mg equivalent to sitagliptin 50 mg     excipient: microcrystalline cellulose opadry pink 85f94203 povidone sodium laurilsulfate sodium stearyl fumarate - janumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus inadequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin. janumet is indicated as part of triple combination therapy with a sulfonylurea as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled with any two of the three agents: metformin, sitagliptin, or a sulfonylurea. janumet is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in combination with premixed or long/intermediate acting insulin.

VELMETIA XR 50/500 sitagliptin (as phosphate monohydrate) 50 mg and metformin hydrochloride 500 mg modified release tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

velmetia xr 50/500 sitagliptin (as phosphate monohydrate) 50 mg and metformin hydrochloride 500 mg modified release tablet bottle

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 500 mg; sitagliptin phosphate monohydrate, quantity: 64.25 mg (equivalent: sitagliptin, qty 50 mg) - tablet, modified release - excipient ingredients: hypromellose; propyl gallate; kaolin; povidone; colloidal anhydrous silica; macrogol 3350; microcrystalline cellulose; sodium stearylfumarate; carnauba wax; titanium dioxide; hyprolose; indigo carmine aluminium lake - velmetia xr (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see sections 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

JANUET 50 MG500 MG Israel - English - Ministry of Health

januet 50 mg500 mg

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - tablets - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 500 mg - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

JANUET 50 MG1000 MG Israel - English - Ministry of Health

januet 50 mg1000 mg

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - tablets - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 1000 mg - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

JANUET 50 MG850 MG Israel - English - Ministry of Health

januet 50 mg850 mg

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - tablets - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 850 mg - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

Janumet New Zealand - English - Medsafe (Medicines Safety Authority)

janumet

merck sharp & dohme (new zealand) limited - metformin hydrochloride 1000mg; sitagliptin phosphate monohydrate 64.25mg equivalent to sitagliptin 50 mg;  ;   - film coated tablet - 50mg/1000mg - active: metformin hydrochloride 1000mg sitagliptin phosphate monohydrate 64.25mg equivalent to sitagliptin 50 mg     excipient: microcrystalline cellulose opadry red 85f15464 povidone sodium laurilsulfate sodium stearyl fumarate - janumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus inadequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin. janumet is indicated as part of triple combination therapy with a sulfonylurea as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled with any two of the three agents: metformin, sitagliptin, or a sulfonylurea. janumet is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in combination with premixed or long/intermediate acting insulin.

Janumet New Zealand - English - Medsafe (Medicines Safety Authority)

janumet

merck sharp & dohme (new zealand) limited - metformin hydrochloride 850mg; sitagliptin phosphate monohydrate 64.25mg equivalent to sitagliptin 50 mg;  ;   - film coated tablet - 50mg/850mg - active: metformin hydrochloride 850mg sitagliptin phosphate monohydrate 64.25mg equivalent to sitagliptin 50 mg     excipient: microcrystalline cellulose opadry pink 85f94182 povidone sodium laurilsulfate sodium stearyl fumarate - janumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus inadequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin. janumet is indicated as part of triple combination therapy with a sulfonylurea as an adjunct to diet and exercise in patients with type 2 diabetes mellitus inadequately controlled with any two of the three agents: metformin, sitagliptin, or a sulfonylurea. janumet is indicated in patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control in combination with premixed or long/intermediate acting insulin.

JANUET 50 MG500 MG Israel - English - Ministry of Health

januet 50 mg500 mg

merck sharp & dohme (israel - 1996) company ltd, israel - metformin hydrochloride; sitagliptin as monohydrate phosphate - tablets - sitagliptin as monohydrate phosphate 50 mg; metformin hydrochloride 500 mg - metformin - metformin - januet is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. important limitations of use:januet should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.januet has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using januet.

APO-SITAGLIPTIN-METFORMIN TABLET Canada - English - Health Canada

apo-sitagliptin-metformin tablet

apotex inc - metformin hydrochloride; sitagliptin (sitagliptin phosphate monohydrate) - tablet - 500mg; 50mg - metformin hydrochloride 500mg; sitagliptin (sitagliptin phosphate monohydrate) 50mg